Mo­tif Bio's turn­around quest for once-re­ject­ed an­tibi­ot­ic hits the CRL wall

For Mo­tif Bio, 2019 was go­ing to be all about the launch and roll­out of iclaprim. But a com­plete re­sponse let­ter from the FDA has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.